Illumina accused of fraud in DNA tech patents dispute
12-01-2021
Duncan_Andison / iStockphoto.com
Genetic sequencing company Illumina and Cornell University have together sought to dismiss a patent dispute over eight genetic testing patents belonging to Cornell.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Illumina, Cornell University, Life Technologies, gene sequencing, patent, agreement
